Durability of combination of insulin and GLP-1 receptor agonist or SGLT-2 inhibitors versus basal bolus insulin regimen in type 2 diabetes: a randomized controlled trial Durability della terapia di combinazione di insulina basale e agonista recettoriale del GLP-1 o SGLT-2 inibitore versus regime di terapia insulinica basal bolus nel diabete tipo 2: studio clinico randomizzato controllato
Latest Information Update: 31 Aug 2021
At a glance
- Drugs Insulin-glargine/lixisenatide (Primary)
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
Most Recent Events
- 31 Aug 2021 New trial record